RCT | Telaglenastat failed to improve the efficacy of Cabozantinib in patients with advanced renal cell carcinoma.

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Commentary on Twitter

The CANTATA randomized trial of the glutaminase inhibitor telagenastat or placebo added to cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) demonstrated no improvement in efficacy with addition of telagenastat https://t.co/r9j2wmjnlF #GUCSM pic.twitter.com/ovXXEAXqi0

— JAMA Oncology (@JAMAOnc) September 1, 2022